These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34887529)

  • 21. Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.
    Correll CU; Stein E; Graham C; DiPetrillo L; Akerman S; Stanford AD; Jiang Y; Yagoda S; McDonnell D; Hopkinson C
    Schizophr Bull; 2023 Mar; 49(2):454-463. PubMed ID: 36305696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials.
    Rehan ST; Siddiqui AH; Khan Z; Imran L; Syed AA; Tahir MJ; Jassani Z; Singh M; Asghar MS; Ahmed A
    Ann Med Surg (Lond); 2022 Jul; 79():104115. PubMed ID: 35860157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine-Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study.
    Sun L; McDonnell D; Liu J; von Moltke L
    Clin Pharmacol Drug Dev; 2019 May; 8(4):459-466. PubMed ID: 30059196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan.
    Sun L; von Moltke L; Rowland Yeo K
    CPT Pharmacometrics Syst Pharmacol; 2020 Feb; 9(2):106-114. PubMed ID: 31919994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet.
    Sun L; Yagoda S; Du Y; von Moltke L
    Drug Des Devel Ther; 2019; 13():2941-2955. PubMed ID: 31686778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
    Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
    Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
    Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review.
    Laguado SA; Saklad SR
    Ment Health Clin; 2022 Aug; 12(4):254-262. PubMed ID: 36071739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance.
    Martins PJ; Haas M; Obici S
    Diabetes; 2010 Oct; 59(10):2418-25. PubMed ID: 20682682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis.
    Peng Z; Jia Q; Mao J; Yi Q
    Neuropsychiatr Dis Treat; 2023; 19():2295-2308. PubMed ID: 37908559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.
    Citrome L; O'Malley SS; McDonnell D; Jiang Y; Simmons AC; Berry MP; Dipetrillo LE
    Innov Clin Neurosci; 2019 May; 16(5-6):15-21. PubMed ID: 31440397
    [No Abstract]   [Full Text] [Related]  

  • 32. The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults.
    Shrewsbury SB; Hocevar-Trnka J; Satterly KH; Craig KL; Lickliter JD; Hoekman J
    J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32609960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine/Samidorphan: First Approval.
    Paik J
    Drugs; 2021 Aug; 81(12):1431-1436. PubMed ID: 34304374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.
    Ballon JS; Pajvani UB; Mayer LE; Freyberg Z; Freyberg R; Contreras I; Rosenbaum M; Leibel RL; Lieberman JA
    J Psychopharmacol; 2018 May; 32(5):533-540. PubMed ID: 29444618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased food intake and energy expenditure following administration of olanzapine to healthy men.
    Fountaine RJ; Taylor AE; Mancuso JP; Greenway FL; Byerley LO; Smith SR; Most MM; Fryburg DA
    Obesity (Silver Spring); 2010 Aug; 18(8):1646-51. PubMed ID: 20134408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
    Corrao MM; Nelson LA
    CNS Drugs; 2022 Jun; 36(6):605-616. PubMed ID: 35644903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.
    Sun L; Mills R; Sadler BM; Rege B
    J Clin Pharmacol; 2021 Nov; 61(11):1430-1441. PubMed ID: 34018607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A low TSH profile predicts olanzapine-induced weight gain and relief by adjunctive topiramate in healthy male volunteers.
    Evers SS; van Vliet A; van Vugt B; Scheurink AJ; van Dijk G
    Psychoneuroendocrinology; 2016 Apr; 66():101-10. PubMed ID: 26802597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
    Smith RC; Lindenmayer JP; Davis JM; Kelly E; Viviano TF; Cornwell J; Hu Q; Khan A; Vaidhyanathaswamy S
    J Clin Psychiatry; 2009 Nov; 70(11):1501-13. PubMed ID: 19814947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
    Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
    Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.